IsoPSA(TM) Demonstration
IsoPSA assay can help in determining the need for prostate biopsy for patients. A team of researchers have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures – distinguishing cancer from benign conditions, and identifying patients with high-risk disease.
By identifying molecular changes in the prostate specific antigen (PSA) protein, the findings, published online last month by European Urology, suggest that once validated, use of IsoPSA may substantially reduce the need for biopsy, and may thus lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. The research team, led by Cleveland Clinic’s Eric Klein, M.D...
Read More
Recent Comments